Phase 2 Completed N=10 Randomized Single-blind Treatment

Almond Butter and Fasting Glucose

Type2 Diabetes

Source: ClinicalTrials.gov NCT03826472 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Nov 2023

Primary outcomePrimary: Fasting Glucose Measured Using Continuous Glucose Monitoring — 148.6; 142.1 mg/dL

Summary

A two-period randomized crossover study will be conducted to determine the effect of almond butter as an evening snack on fasting blood glucose in adults with type 2 diabetes, not taking insulin.

Outcome Measures

Outcome	Result	p-value
PRIMARY Fasting Glucose Measured Using Continuous Glucose Monitoring	148.6; 142.1	—
SECONDARY Glucose Trends	147.7; 142.2	—
SECONDARY Inhibitory Control Task (Percent Correct)	35.34; 35.51	—

Eligibility Criteria

Inclusion Criteria

Individuals with diagnosed type 2 diabetes
Not on insulin therapy
On stable does of oral antihyperglycemic agent (no dose change for 6 months)
Currently monitoring blood glucose at home via glucometer
Willing and able to adhere to study protocol

Exclusion Criteria

Individuals with type 1 diabetes, cardiovascular disease, kidney disease, liver disease, cancer or inflammatory conditions (e.g. GI disorders, rheumatoid arthritis)
Women who are pregnant, breastfeeding, or have been pregnant within the last 6 months or breastfeeding within the last 6 weeks
Individuals who smoke or use tobacco products
Use of insulin therapy or sulfonylurea medications
Allergy to any tree nut
Liver or kidney disease
Allergy to Dexcom CGM adhesive

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03826472). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.